logo
Twitter
Discord
Email
logo
GSK plc

GSK plc

NYSE•GSK
CEO: Ms. Emma Natasha Walmsley
Sector: Healthcare
Industry: Drug Manufacturers - General
Listing Date: 1980-03-28
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Contact Information
980 Great West Road, Middlesex, Brentford, TW8 9GS, United Kingdom
44-20-8047-5000
www.gsk.com
Market Cap
$95.93B
P/E (TTM)
21.2
50
Dividend Yield
3.3%
52W High
$48.69
52W Low
$31.72
52W Range
91%
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$273.62B+3315.12%
4-Quarter Trend

EPS

$5.72-20240.84%
4-Quarter Trend

FCF

$0.00-100.00%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Total Turnover Increased Group turnover reached £31.4bn, growing 3% AER and 7% CER, driven by Specialty Medicines momentum.
Specialty Sales Grew Strongly Specialty Medicines turnover hit £11.8bn, showing 15% AER growth and 19% CER growth across HIV, Oncology, and RI&I.
Strong R&D Pipeline Progress GSK maintains 71 assets in development pipeline, including 19 assets currently in Phase III or registration stage.
Share Buyback Announced Board announced intention to execute a £2B share buyback programme over the next 18 months, supporting shareholder returns.

Risk Factors

Zantac Settlement Impacted Profit Total operating profit fell 40% to £4.021B, heavily impacted by an £1.8B charge for the Zantac settlement.
Vaccines Sales Decreased Vaccines turnover was £9.1bn, declining 7% AER and 4% CER, reflecting external pressures in key markets like the US.
Evolving Regulatory Environment Risks remain from evolving global regulations, geopolitical tensions, and potential restrictions on high GWP propellant use in inhalers.
Ongoing Cyber Security Threats Failure to protect information systems against cyber threats risks patient harm, business disruption, and loss of strategic advantage.

Outlook

Focus on Major Product Launches Expecting five major launches in 2025 alone, driven by pipeline progression and continued investment in RI&I and Oncology assets.
Invest for Growth and Returns First priority for capital remains investing in growth (R&D and BD), coupled with progressive dividend policy and share buybacks.
Advancing Ultra-Long-Acting HIV Aiming for treatment and prevention dosing intervals of every four to six months, including potential self-administered options by decade end.
Lower Carbon Inhaler Development Investing in R&D to redevelop Ventolin inhalers with low-carbon propellant, potentially reducing emissions by approximately 90%.

Peer Comparison

Revenue (TTM)

CVS Health CorporationCVS
$394.08B
+6.8%
McKesson CorporationMCK
$387.09B
+17.2%
GSK plcGSK
$297.24B
+849.3%

Gross Margin (Latest Quarter)

Vertex Pharmaceuticals IncorporatedVRTX
86.5%
+0.7 pp
SanofiSNY
74.1%
+2.9 pp
Bristol-Myers Squibb CompanyBMY
71.9%
+16.3 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SNY$128.34B12.012.4%10.4%
HCA$114.73B18.0-161.9%77.6%
VRTX$112.18B30.419.6%7.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
+223.0%
Strong Growth
4Q Net Income CAGR
+203.8%
Profitability Improved
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 3, 2025|
    Revenue: $40.09B+3.5%
    |
    EPS: $1.61-48.4%
    Beat

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 5, 2024|
    Revenue: $37.71B+3.4%
    |
    EPS: $3.03+0.0%
    Miss

  • Form 20-F/A - FY 2022

    Period End: Dec 31, 2022|Filed: Apr 17, 2023|
    Revenue: $35.29B-14.0%
    |
    EPS: $2.94-10.9%
    Miss

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Mar 10, 2023|Refer to amended data

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Mar 8, 2022|
    Revenue: $33.97B+0.0%
    |
    EPS: $3.77-4.9%
    Meet

  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Mar 12, 2021|
    Revenue: $31.24B+1.0%
    |
    EPS: $3.69+23.1%
    Meet